Rezo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rezo Therapeutics, Inc. - overview
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and co-founded by Nevan Krogan (CEO), Kevan Shokat, Sourav Bandyopadhyay (CSO), Natalia Jura, George Scangos (Chairperson), and Norbert Bischofbergerin, Rezo Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing a technology platform to enhance the success rate of drug development. In November 2022, the firm raised USD 78 million in series A funding co-led by new investors a16z, Norwest Venture Partners, and SR One, with participation from other investors Hawktail Management, Liquid 2 Ventures, and SV Angel. The company offers a Sequence to Systems to Drugs (SSD) platform that through computational methods enables the integration of data from proteomics, genetics, structural biology, and chemical biology and creates comprehensive maps of molecular disease networks to provide more complete and rapid view of mechanisms that causes disease.
The platform through artificial intelligence and machine learning, identifies and study disease-causing protein and genetic interactions, and elevates the rate of medication development and its effectiveness for a range of diseases. Rezo as of January 2023 is initially focusing on oncology. The company plans to utilize its November 2022 funding to support its product research and development.
Current Investors
Norwest Venture Partners, SR One, Andreessen Horowitz
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.rezotx.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.